Recently an innovative chemical strategy for the facile synthesis of tetrabranched peptide derivatives has been developed and named peptide welding technology (PWT) . The PWT has been applied to different peptide sequences including nociceptin/ orphanin FQ (N/OFQ) , neuropeptide S , and tachykinins (substance P, neurokinin A and B) . These studies demonstrated that PWT derivatives maintained the in vitro pharmacological profile (pharmacological activity, potency and selectivity of action) of the parent peptide sequences while showing higher in vivo potency and particularly long lasting action.
Previous studies demonstrated that [Dmt 1 ]N/OFQ(1-13)-NH 2 behaves as a universal agonist for N/OFQ (NOP) and classical opioid receptors (Molinari et al., 2013) . In particular, the mixed NOP/opioid full agonist activity and high affinity/potency of [Dmt 1 ]N/OFQ(1- ]N/ OFQ(1-13)-NH 2 given intrathecally (i.t.) elicited robust and longlasting antinociceptive effects (Molinari et al., 2013) .
Thus, the purpose of the present study was to investigate the pharmacological profile of the PWT derivative of [Dmt 1 ]N/OFQ(1-13)-
The PWT2 derivative of [Dmt 1 ]N/OFQ(1-13) was prepared by using a convergent synthetic approach and methodology previously applied for the synthesis of PWT derivatives of N/OFQ , Neuropeptide S and tachykinins . Firstly, [Dmt
Cys 14 ]N/OFQ(1-14)-NH 2 was synthesized by solid phase method with an automatic solid phase peptide synthesizer Syro II (Biotage, Uppsala Sweden) using Fmoc/tBu chemistry (Benotoin, 2005) . The resin 4-(2′,4′-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucyl-MBHA (Rink amide MBHA resin) was used as a solid support. The resin was treated with 40% piperine/ N,N-dimethylformamide (DMF) and linked with FmocCys(Trt)-OH by using [O-(7-azabenzotriazol-1-yl)−1,1,3,3-tetramethyluronium hexafluorophosphate] (HATU) as the coupling reagent. The following Fmoc amino acids were sequentially coupled to the growing peptide chain: Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Thr( t Bu)-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Dmt-OH (Dmt: 2′,6′-dimethyl tyrosine). All the Fmoc amino acids (4 equiv) were coupled to the growing peptide chain by using HATU (4 equiv) in DMF in the presence of an equimolar concentration of 4-methylmorpholine (NMM), and the coupling reaction time was 1 h. To improve the analytical profile of the crude peptide, capping with acetic anhydride (0.5 M/DMF) in the presence of NMM (0.25 M/DMF) (3:1 v/v; 2 ml/ 0.2 g of resin) was performed at any step. 40% Piperidine/DMF was used to remove the Fmoc. The protected peptide-resin was treated with reagent B (Sole and Barany, 1992 ) (trifluoroacetic acid (TFA)/H 2 0/ phenol/triisopropylsilane 88:5:5:2; v/v; 10 ml/0.2 g of resin) for 1.5 h at room temperature. After filtration of the resin, the solvent was concentrated in vacuum and the residue triturated with ethyl ether. Crude [Dmt 1 Cys 14 ]N/OFQ(1-14)-NH 2 was purified by preparative reversed-phase HPLC using a Water Delta Prep 3000 system with a Jupiter column C 18 (250×30 mm, 300 A, 15 µm spherical particle size). The column was perfused at a flow rate of 20 ml/min with a mobile phase containing solvent A (5%, v/v, acetonitrile in 0.1% TFA), and a linear gradient from 5% to 40% of solvent B (60%, v/v, acetonitrile in 0.1% TFA) over 25 min for the elution of the peptide. core in a classical thio-Michael reaction using experimental conditions previously optimized for the synthesis of N/OFQ tetra branched derivatives N/OFQ(1-13) were determined using a Luna C 18 column (4.6×100 mm, 3 µm particle size) with the above solvent system (solvents A and B) programmed at a flow rate of 0.5 ml/min using a linear gradient from 0% to 50% B over 25 min. Final product showed ≥95% purity when monitored at 220 nm. Molecular weight of PWT2-
) was in accord with the expected molecular formula.
Membrane preparation
Cells were harvested, homogenized, and membrane fragments were resuspended in a wash buffer either consisting of 50 mM Tris-HCl pH to 7.4 with KOH, for CHO mu , CHO delta , and CHO kappa or supplemented with 5 mM MgSO 4 for CHO NOP cells in displacement binding assays, or in an homogenization buffer (50 mM Tris and 0.2 mM EGTA pH 7.4 with NaOH) in [ 35 S]GTPγS functional assays. The membrane suspensions were centrifuged and homogenized at 20,374g at 4°C for 10 min repeating this process a total of 3 times. The resulting pellet was resuspended in an appropriate volume of the desired buffer and protein concentration measured using the Lowry assay (Lowry et al., 1951) .
Receptor binding assay
Membrane protein (20-40 µg) was incubated in 0.5 ml of 50 mM Tris, 0.5% BSA and~0.8 nM [
3 H]-DPN for classical opioid or~0.8 nM
]-UFP-101 for NOP receptors, as well as varying concentrations (1 pM-10 μM) of the control ligands and test compounds. Non-specific binding was determined in the presence of 10 μM naloxone or 1 µM of N/OFQ for classical opioid and NOP receptors, respectively. Samples were incubated for 1 h at room temperature, following which reactions were terminated by vacuum filtration, onto PEI-soaked Whatman GF/ B filters, using a Brandel harvester.
Stimulated [

S]GTPγS binding assay
Membrane protein (20-40 µg) was incubated in 0.5 ml volume of 50 mM Tris, 0.2 mM EGTA, 1 mM MgCl 2, 100 mM NaCl, 0.1% BSA, 0.15 mM bacitracin; pH 7.4, GDP (33 μM), and ∼150 pM [ (1 pM -10 µM) was added prior to incubation. Nonspecific binding was determined in the presence of unlabeled GTPγS (10 µM). Samples were incubated for 1 h at 30°C with gentle agitation. Reactions were terminated by vacuum filtration through dry Whatman GF/B filters, using a Brandel harvester.
Calcium mobilization assay
CHO cells stably coexpressing either human recombinant NOP, mu or kappa receptor along with the C-terminally modified Gα qi5 chimeric protein and cells co-expressing the delta receptor and the Gα qG66Di5 chimeric protein were generated as previously described Camarda et al., 2009 ). Cells were cultured in culture medium consisting of Dulbecco's modified Eagle's medium (DMEM)/ HAMS F12 (1:1) supplemented with 10% fetal bovine serum (FBS), penicillin (100 IU/ml), streptomycin (100 µg/ml), L-glutamine (2 mM); fungizone (1 µg/ml), geneticin (G418; 200 µg/ml) and hygromycin B (100 µg/ml). Cell cultures were kept at 37°C in 5% CO 2 / humidified air. Cells were seeded at a density of 50,000 cells/well into 96-well black, clear-bottom plates. After 24 h incubation the cells were loaded with Hank's Balanced Salt Solution (HBSS) supplemented with 2.5 mM probenecid, 3 µM of the calcium sensitive fluorescent dye Fluo-4 AM, 0.01% pluronic acid and 20 mM HEPES (pH 7.4) for 30 min at 37°C. Afterwards the loading solution was aspirated and a washing step with 100 µl/well of HBSS, HEPES (20 mM, pH 7.4), 2.5 mM probenecid and 500 µM Brilliant Black was carried out. Subsequently 100 µl/well of the same buffer was added. After placing cell culture and compound plates into the FlexStation II (Molecular Devices, Sunnyvale, CA, USA), fluorescence changes were measured after 10 min of stabilization at 37°C. On-line additions were carried out in a volume of 50 µl/well.
BRET assay
Human Embryonic Kidney (HEK-293) and human SH-SY5Y neuroblastoma cells were grown in Dulbecco's modified Eagle's medium (DMEM) or Dulbecco's MEM/HAM'S F-12 (50/50) supplemented with 10% (v/v) FBS, penicillin G (100 IU/ml), streptomycin (100 µg/ml), Lglutamine (2 mM); fungizone (1 µg/ml), geneticin (G418; 200 µg/ml) and hygromycin B (100 µg/ml) either in a humidified atmosphere of 5% CO 2 at 37°C. Cells lines permanently co-expressing the different pairs of fusion proteins, NOP-RLuc/Gβ1-RGFP and NOP-RLuc/β-arrestin 2-RGFP (HEK293), mu-RLuc/Gβ1-RGFP and mu-RLuc/β-arrestin 2-RGFP (SH-SY5Y) were prepared using the pantropic retroviral expression system by Clontech as described previously (Molinari et al., 2010) . For G-protein experiments enriched plasma membrane aliquots from transfected cells were prepared and quantified as previously described in detail . Luminescence in membranes was recorded in 96-well untreated white opaque microplates, while in whole cells in 96-well sterile poly-D-lysine-coated white opaque microplates for HEK-293 and in untreated white opaque microplates for SH-SY5Y cells using the luminometer Victor 2030 (PerkinElmer, Waltham, MA, USA). For the determination of receptor/ G-protein interaction, membranes (3 μg of protein) prepared from cells co-expressing NOP/RLuc-Gβ1/RGFP or mu/RLuc-Gβ1/RGFP were added to wells in DPBS. For the determination of receptor/β-arrestin 2 interaction, cells co-expressing NOP/RLuc-β-arrestin 2/RGFP or mu/RLuc-β-arrestin 2/RGFP were plated 24 h before the experiment (100,000 cells well
−1
). The cells were prepared for the experiment substituting the medium with PBS with MgCl 2 (0.5 mM) and CaCl 2 (0.9 mM). Coelenterazine at a final concentration of 5 μM was injected 15 min prior reading the cell plate. Different concentrations of ligands in 20 µl of PBS-BSA 0.01% were added and incubated 15 min before reading luminescence. All the experiments were performed at room temperature.
Materials and drugs
All cell culture media and supplements were from Invitrogen (Paisley, U.K.). All other reagents used were from Sigma Chemical Co. (Poole, UK) or E. Merck (Darmstadt, Germany) and were of the highest purity available. Dermorphin, N/OFQ, [Dmt 1 ]N/OFQ(1-13)-NH 2 and PWT2- [Dmt 1 ] were synthesized in house (Department of Chemical and Pharmaceutical Sciences, University of Ferrara) as previously described (Guerrini et al., 1997 , while J-113397, DPDPE, and dynorphin A were bought from Tocris Bioscience (Bristol, UK). Naltrexone HCl was from National Institute on Drug Abuse (Bethesda, MD, USA). Tritiated UFP-101 ([ 3 H]-UFP-101) was synthesized as described previously (Ibba et al., 2008 ] were made in ultrapure water and all stored at −20°C until use. The successive dilutions were made in HBSS/ HEPES (20 mM) buffer (containing 0.005% Bovine Serum Albumin (BSA) fraction V to avoid licking) in the calcium assay and PBS/BSA (0.01%) buffer in the BRET assay.
Animals
Four adult male and female rhesus monkeys (Macaca mulatta, aged 11-18 years old) weighing between 7.7 and 14 kg were used. Monkeys were individually housed and their daily diet consisted of approximately 25-30 biscuits (Purina Monkey Chow; Ralston Purina Co., St. Louis, MO, USA), fresh fruit, and water ad libitum. For 1 month before the present study, the monkeys were not exposed to any drugs. All monkeys had previously been trained in the warm water tailwithdrawal assay and they were housed in facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care/AAALAC International. All animal care and experimental procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the US National Institutes of Health (Bethesda, MD, USA) and approved by the Institutional Animal Care and Use Committee of Wake Forest University (Winston-Salem, NC, USA). All studies are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny et al., 2010) .
In vivo studies
The warm water tail-withdrawal assay (Ko and Naughton, 2009 ) was used to evaluate thermal antinociceptive effect of PWT2-[Dmt 1 ].
Monkeys were seated in primate restraint chairs, and the lower parts of their shaved tails (approximately 15 cm) were immersed in a thermal flask containing water maintained at either 42, 46, or 50°C. Water at 42 and 46°C was used as non-noxious stimuli, and 50°C water was used as an acute noxious stimulus. Tail-withdrawal latencies were measured at each temperature by using a computerized timer by experimenters who were blinded to experimental conditions. If the monkeys did not remove their tails within 20 s (cut-off), the flask was removed and a maximum time of 20 s was recorded. Test sessions began with baseline measurements at each temperature. Subsequent tail-withdrawal latencies were measured at multiple time points after i.t administration of PWT2- [Dmt 1 ]. Behavioural activities of monkeys were recorded in their home cages for quantifying scratching responses, which is associated with itch sensation (Ko et al., 2004) . Each 15-min recording session was conducted at multiple time points after i. ] was administered i.t. in a volume of 1 ml through the subcutaneous access port in monkeys implanted with intrathecal catheters . Naltrexone and J-113397 were administered subcutaneously in a volume of 0.1 ml/kg. There was a minimum of 1-week interval between drug administrations.
We first characterized the effectiveness and duration of PWT2- ]-mediated antinociception, we selected a fully effective antinociceptive dose (3 nmol) to determine if this dosing condition increased scratching behaviour (Ko et al., 2004) . In addition, we selected a single dose 0.03 mg/kg of naltrexone and 0.1 mg/kg of J-113397, known to selectively produce mu and NOP receptor antagonist effects, respec-tively, in monkeys (Hu et al., 2010) . Either antagonist was administered subcutaneously 1 h and 10 min after i.t. administration of 3 nmol of PWT2-[Dmt 1 ].
Data analysis and terminology
All data are expressed as means ± standard error of the mean (S.E.M.) of at least 3 experiments performed in duplicate. For potency values 95% confidence limits were indicated. The pharmacological terminology adopted in this report is consistent with the IUPHAR recommendations (Neubig et al., 2003 
Where IC 50 is the concentration of antagonist that produces 50% inhibition of the agonist response, [L] is the concentration of free radioligand and K D is the dissociation constant of the radioligand for the receptor. Agonist potencies were given as pEC 50 that is the negative logarithm to base 10 of the molar concentration of an agonist that produces 50% of the maximal possible effect. Maximal effects elicited by the agonists are expressed as intrinsic activity α using the control ligand as full agonist (α=1.00). Concentration response curve to agonists were fitted with the four parameter logistic nonlinear regression model:
Where EC 50 is the concentration of agonist producing a 50% maximal response, X is the agonist concentration and n is the Hill coefficient of the concentration response curve to the agonist. Curve fittings were performed using Graph Pad PRISM 5.0 (GraphPad Software In., San Diego, U.S.A. GTPγS) with one way ANOVA followed by the Bonferroni's test for multiple comparisons. In both cases P values less than 0.05 were considered to be significant. Antinociceptive effects were quantified in each animal as % maximum possible effect (MPE) at each time point and drug dose. The following formula was used to calculate %MPE: %MPE=[(Post-drug value for a behavioural response (s) -Pre-drug value for a behavioural response (s)/(Cutoff value 20 s -Pre-drug value for a behavioural response(s)) ×100]. If the animal did not withdraw its tail before the cut-off value, 100% MPE was assigned. Mean values (mean ± S.E.M.) were calculated from individual animals for all behavioural end points. All in vivo data were analyzed by two-way analysis of variance with repeated measures followed by Bonferroni's multiple comparisons test. The criterion for significance for all tests was set at P < 0.05.
Results
Displacement Binding assay
In CHO NOP cell membranes, N/OFQ ] displayed a significant decrease in affinity (pK i 9.13) when compared to the parent compound [Dmt 1 ]N/OFQ(1-13)-NH 2 ( Fig. 2A) ]N/OFQ(1-13)-NH 2 (pK i 10.4) demonstrated higher affinity than dermorphin (9.14), while the affinity of the tetrameric compound was superimposable to that of dermorphin (9.25) (Fig. 2B) ] showed an~18 fold loss of affinity compared to its patent compound (Fig. 2C ). Furthermore, all tested compounds displaced the binding of [ (Fig. 2D) . ]N/OFQ(1-13)-NH 2 and its PWT derivative produced significantly higher maximal responses (2.51 ± 0.17 fold, 2.43 ± 0.08 fold) compared to that elicited by the endogenous compound dynorphin A (2.03 ± 0.04 fold) (Fig. 3C) ] elicited slightly lower maximal effects with potency 8 and 23 fold lower than DPDPE (Fig. 4D) . The values of potency and efficacy of [Dmt 1 ]N/OFQ(1-13)-NH 2 and its PWT derivative are summarized in Table 3 .
BRET assay
The ability to promote receptor/G protein and receptor/β-arrestin 2 interaction of standard ligands, (i.e. N/OFQ for the NOP receptor and dermorphin for the mu receptor), [Dmt 1 ]N/OFQ(1-13)-NH 2 and its PWT derivative, has been assessed using a BRET based assay. As shown in Fig. 5A , in membranes prepared from cells HEK-293 expressing the NOP receptor, N/OFQ, [Dmt 1 ]N/OFQ(1-13)-NH 2 and its PWT derivative promoted receptor/G protein interaction in a concentration dependent manner with similar potency and maximal effects. Under the same experimental conditions, membranes extracted from SH-SY5Y cells were used to evaluate the activity of the compounds at the mu receptor. Dermorphin promoted mu/G-protein interaction in a concentration dependent manner with high potency. ] at micromolar concentrations elicited stimulatory effect higher than those of the standard (Fig. 5B) . These results are summarized in Table 4 .
In HEK-293 cells expressing the NOP receptor N/OFQ promoted receptor/β-arrestin 2 interaction in a concentration dependent manner with high potency. [Dmt 1 ]N/OFQ(1-13)-NH 2 mimicked the stimulatory effect of the standard with similar potency but with a lower maximal response. PWT2-[Dmt 1 ] showed a lower potency and efficacy compared to the standard and parent compound, behaving as partial agonist (Fig. 6A) . In SH-SY5Y cells expressing the mu receptor dermorphin promoted receptor/β-arrestin 2 interaction in a concentration dependent manner with high potency. ] acted in a similar manner to the parent compound but with slightly lower potency (Fig. 6B) . ] at G protein and arrestin are plotted in the same graph. It can be seen that the PWT modification favoured G protein vs arrestin potency and efficacy; this applies to both NOP and mu receptors. This is made clearer in Fig. 8 where the bias plot obtained by plotting the amount of signal produced in the G protein pathway as a function of equal amounts of signal produced in the arrestin pathway in response to equimolar concentrations of agonist (Kenakin, 2014) . The results obtained in BRET studies were summarized in Table 5 . ]-induced antinociception while naltrexone 0.03 mg/kg was inactive.
Discussion
Previous studies demonstrated that [Dmt 1 ]N/OFQ(1-13)-NH 2 behaves as a potent agonist for NOP and classical opioid receptors and elicits robust antinociceptive effects after spinal administration in non-human primates (Molinari et al., 2013) . The recently developed PWT strategy has been applied to [Dmt 1 ]N/ OFQ(1-13)-NH 2 generating the tetrabranched derivative PWT2- ] elicited antinociceptive effects and was at least 10 fold more potent than [Dmt 1 ]N/OFQ(1-13)-NH 2 and produced longer lasting effects. Collectively this study corroborated previous findings Ruzza et al., 2014 Ruzza et al., , 2015 demonstrating that the PWT approach can be applied to the peptide sequence of different GPCR peptide agonists to generate novel ligands characterized by a similar in vitro pharmacological profile associated with high potency and long lasting action in vivo.
In receptor binding studies performed on membranes from cells expressing recombinant human receptors standard ligands for NOP and opioid receptors i.e. N/OFQ, dermorphin, dynorphin A and DPDPE displayed high affinity for their respective receptors with pK i values in line with previous findings (Molinari et al., 2013; Reisine, 1995) . [Dmt 1 ]N/OFQ(1-13)-NH 2 was able to displace radioligand binding at the four receptors with the following rank order of affinity NOP = mu = kappa > delta. These results perfectly match previous studies both in terms of absolute values and rank order of affinity corroborating the proposal of [Dmt 1 ]N/OFQ(1-13)-NH 2 as a universal opioid receptor ligand (Molinari et al., 2013 ] displaced an amount of radioactivity higher than N/OFQ. We interpret these perplexing results as due to the presence of displaceable nonspecific binding, a phenomenon relatively common when N/OFQ or N/OFQ related peptides are used as radioligands (Dooley and Houghten, 2000) . ]N/OFQ(1-13)-NH 2 sequence does not modify its pharmacological activity i.e. full agonism. This finding is in line with a large series of previous studies in which the pharmacological activity of different peptide sequences including the full agonists N/OFQ , substance P, neurokinin A and B , neuropeptide S , and dermorphin (Ferrari et al., unpublished) was maintained by PWT derivatives.
The calcium mobilization assay used to characterize the pharmacological profile of PWT2-[Dmt 1 ] has been previously validated with a large panel of NOP and opioid ligands Camarda et al., 2009 ) and the standard agonists used in the present investigation displayed potencies and selectivity profiles in line with the above mentioned studies. [Dmt 1 ]N/OFQ(1-13)-NH 2 mimicked the stimulatory effects of standards at the four receptors displaying similar maximal effects and the following rank order of receptor potency NOP > mu = kappa > delta. Superimposable results were previously obtained both in terms of absolute potencies and selectivity profile (Molinari et al., 2013 1.43 ± 0.12 N/OFQ and dermorphin were used as reference agonists for calculating intrinsic activity at NOP and mu receptors, respectively. crc incomplete means that maximal effects could not be determined due to the low potency of the compounds. 0.82 ± 0.07 N/OFQ and dermorphin were used as reference agonists for calculating intrinsic activity at NOP and mu receptors, respectively. Inactive means that the compound was inactive up to 1 µM. M.C. Cerlesi et al. European Journal of Pharmacology 794 (2017) 115-126 et al., 2014), substance P, neurokinin A and B , and dermorphin (Ferrari et al., unpublished) but not with neuropeptide S . The loss in agonist potency of PWT derivatives in the calcium mobilization assay has been interpreted as a due to nonequilibrium conditions (Charlton and Vauquelin, 2010) . In fact PWT derivatives display slow kinetics of action as revealed in isolated tissue experiments Ruzza et al., 2014) . The relatively long time needed to obtain full receptor activation by slowly equilibrating agonists is not compatible with the rapid and transient nature of the calcium response (Charlton and Vauquelin, 2010 ] to promote receptor interaction with G protein and β-arrestin 2 has been previously validated for classical opioid (Molinari et al., 2010) as well as NOP receptors and then used for characterizing novel ligands (Asth et al., 2016; Bird et al., 2016; Rizzi et al., 2016) or for selecting the best compounds for inducing receptor stability and crystallogenesis (Miller et al., 2015) . In line with previous findings Rizzi et al., 2016) and opioid (Molinari et al., 2010) ] behaved as a G protein biased agonist both at NOP and mu receptors. Similar results have been previously obtained by applying the PWT technology to N/OFQ. In fact an inversion in the rank order of potency between N/OFQ and PWT2-N/OFQ was measured in NOP/G protein and NOP/β-arrestin studies. PWT2-N/OFQ was more potent than the natural agonist in promoting G protein interaction, but less potent than N/OFQ in inducing arrestin interaction . Thus similar to PWT2-[Dmt 1 ], PWT2-N/OFQ also behaved as G protein biased agonist. The interpretation of these findings is far from being obvious. In fact the N-terminal pharmacophoric peptide sequences i.e. Phe-Gly-Gly-Phe and Dmt-Gly-Gly-Phe of N/OFQ and [Dmt 1 ]N/OFQ(1-13)-NH 2 , respectively, are identical in the PWT derivatives of the two peptides and recent receptor structure (Thompson et al., 2012; Miller et al., 2015) and modelling (Daga and Zaveri, 2012; Kothandan et al., 2014) studies demonstrated that receptor activation is triggered by the occupation of the NOP receptor binding pocked by these sequences. Eventually when linked together into the PWT structure the N-terminal pharmacophoric sequences lose the ability to adopt some conformational states that are more important for promoting the interaction of the receptor with β-arrestin than with G protein. However these are mere speculations that should be validated experimentally by solving the structure of the NOP receptor in complex with peptides, their PWT derivatives, G protein and β-arrestin. Moreover the ability to promote G protein biased agonism by applying the PWT chemical modification is not a general phenomenon. This has been demonstrated for the PWT derivatives of N/OFQ and [Dmt 1 ]N/OFQ(1-13)-NH 2 but not for PWT2-dermorphin. In fact, the latter peptide maintained the unbiased behaviour of the natural peptide in BRET experiments (Ferrari et al., unpublished) .
Previous studies demonstrated that after spinal administration in monkeys [Dmt 1 ]N/OFQ(1-13)-NH 2 elicits a robust and dose dependent (1 -10 nmol) antinociceptive effect (Molinari et al., 2013 elicit statistically significant effects even 24 h after injection. These results confirm and extend previous findings Ruzza et al., 2014 Ruzza et al., , 2015 demonstrating that the PWT strategy generates tetrabranched derivatives characterized by a pharmacological profile similar to the native peptide in vitro, but associated with a higher potency and a marked prolongation of action in vivo. Antagonist experiments were performed in order to investigate the receptor(s) involved in the antinociceptive action of PWT2 Similar results were previously obtained with NOP selective agonists such as N/OFQ (Ko et al., 2006) and UFP-112 (Hu et al., 2010 ] in in vitro functional assays. Species specific differences may account for this discrepancy although available evidence suggests no major pharmacological differences between human and monkey NOP receptors (Koga et al., 2009) . Further studies are needed in order to modify the [Dmt 1 ]N/OFQ(1-13)-NH sequence with the aim of generating a mixed NOP/opioid ligand with exactly the same potency at NOP and mu receptors. The PWT derivative of such ligand may promote robust and long lasting analgesic effects based on the well described synergistic action of NOP and mu receptor activation (reviewed in Toll et al. (2016) ). The promising results obtained with the mixed agonist cebranopadol in preclinical Rizzi et al., 2016) as well as clinical studies (Lambert et al., 2015) corroborate this proposal.
In conclusion this study demonstrated that the application of the PWT technology to the peptide sequence of [Dmt 1 ]N/OFQ(1-13)-NH 2 generated a tetrabranched derivative that maintains in vitro the universal opioid agonist features of the parent peptide associated with a certain degree of G protein biased agonism. Confirming previous findings obtained with different peptide sequences, the in vivo action of PWT2 ] in non human primates, at least in the examined range of doses, was exclusively due to NOP receptor activation.
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